Sep 02,2020

Evidation Study Validates Key Outcomes for Omada Diabetes Program

Continuing the company’s commitment to rigorous measurement of its digital care programs, Omada Health today announced the results of a clinical study run in collaboration with Evidation Health. The study took place from November 2019 through July 2020, meaning participants maintained engagement, and achieved results, throughout the COVID-19 public health emergency. The study was conducted using Evidation’s Achievement platform and population. The study population included 195 participants with a diagnosis of Type 2 Diabetes, and an average starting baseline A1c of 8.93%. Full study results will be published later this year.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Sep 17,2020

Largescale Real-World Migraine Study Solidifies Efficacy And Safety of Theranica’s Nerivio® Device

Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced the publication of a new real-world post-marketing surveillance study in Pain Medicine that demonstrates the safety, efficacy and consistency of the company's Nerivio® therapeutic wearable device. The study evaluated two cohorts of patients with episodic and chronic migraine. One group utilized in-person visits with headache specialists, while the other cohort included patients who were managed through a single-specialty or multi-specialty online telemedicine platform. Observed patients used Theranica's Nerivio without complementary treatments.

CLINICAL STUDY

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Sep 29,2020

Internet CBT for pediatric OCD maintains, or even increases, effectiveness over 12 months

New data suggest that an Internet-delivered cognitive behavioral therapy (ICBT) intervention not only remained effective after 12 months among adolescents with obsessive-compulsive disorder, but seemed to have an even greater impact on their symptoms with time. The average age of the 61 adolescents who received ICBT was about 14-and-a-half. The researchers found a significant increase in responses between the three-month and 12-month check-ins, with the latter having increased to a rate of 73%. The researchers saw a similar nine-month jump in remitters.

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Oct 08,2020

Smoking cessation app Quit Genius proves to be effective in the short term

The smoking-cessation digital-therapeutic app Quit Genius was found to be an effective treatment for people trying to stop smoking, especially when they are compared to individuals seeking out their own regimen, according to new research from JMIR Mental Health. Quit Genius’ treatment relies on cognitive behavioral therapy to guide users through a year-long smoking cessation program. It uses strategies like self-monitoring, goal setting, encouraging medication adherence and providing feedback on progress to guide users through the program. Users also have access to a quit coach, an advisor qualified by the U.K.'s National Centre for Smoking Cessation and Training, to guide and support them.

CLINICAL STUDY

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 21,2020

Researchers Present New Outcome Data for Akili Digital Therapeutic EndeavorRx™ in Pediatric ADHD

Akili today announced multiple data presentations on EndeavorRx, including results from the STARS-Adjunct trial, a multi-site open-label study designed to evaluate the impact of EndeavorRx™ on impairments in daily life in children with attention-deficit/hyperactivity disorder (ADHD) and inform prescribing practices. Key results across the presentations include: Improvements in the ADHD Impairment Rating Scale (IRS) were statistically significant compared to baseline and were similar in magnitude regardless of whether or not children were taking stimulant medication, and parent observations showed half of children responded to treatment following one month of EndeavorRx use and improvements remained stable for one month following treatment

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 26,2020

NeuroSigma Announces Publication of ADHD Clinical Trial Data That Provide Additional eTNS Mechanism of Action

The paper presents results of research conducted at UCLA as part of the pivotal trial of external TNS (eTNS) for pediatric ADHD that supported NeuroSigma’s FDA clearance of the Monarch eTNS System. The objective of the research was to explore the applicability of a precision medicine approach to Trigeminal Nerve Stimulation by testing secondary outcomes of cognitive and electrophysiological (EEG) predictors of treatment response among subjects from the original randomized controlled trial.

CLINICAL STUDY

#connected device

View Analyst & Ambassador Comments
Go to original news
Nov 03,2020

How digital health can reveal if a patient’s asthma or COPD is under control

Digital health tools are used to track patient health data over time and provide insight into important trends overlooked when looking at single data points during a patient’s visit with a healthcare provider. The data collected by these tools has great potential when integrated with the patient’s clinical care. Propeller’s research team has been digging into this topic and recently presented their findings at the 2020 European Respiratory Society (ERS) International Congress, which was virtual this year due to the coronavirus pandemic.

CLINICAL STUDY

#connected device

View Analyst & Ambassador Comments
Go to original news
Nov 03,2020

Omada Digital Diabetes Prevention Program Shows Sustained HbA1c Reduction and Weight Loss in Randomized Control Trial

Outcomes of the Preventing Diabetes with Digital Health and Coaching for Translation and Scalability (“PREDICTS”) Randomized Controlled Trial (“RCT”) presented at ObesityWeek® Interactive demonstrate Omada Health’s Digital Diabetes Prevention Program (d-DPP) achieved a statistically significant and clinically meaningful improvement in Hemoglobin A1c reduction and weight loss over a 12-month period.

CLINICAL STUDY

#coaching

View Analyst & Ambassador Comments
Go to original news
Nov 05,2020

Pear Therapeutics Announces Publication of Real-World Healthcare Resource Utilization Data for reSET-O®

Pear Therapeutics, Inc. today announced publication of real-world data analyzing healthcare resource utilization for reSET-O®, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD), in the peer-reviewed journal Expert Review of Pharmacoeconomics & Outcomes Research. The new real-world data showed a robust decrease in costly healthcare utilization categories in patients with OUD. Decreased healthcare utilization reduced overall healthcare spend by $2,150 per patient.

CLINICAL STUDY

#pdt

View Analyst & Ambassador Comments
Go to original news
Nov 09,2020

Respiratory platform NuvoAir shows high acceptance of its home spirometry

Studies on paediatric pulmonology from the UK and Sweden have demonstrated that both young and adult patients with respiratory disease can achieve good quality spirometry at home, without clinical supervision, when using the NuvoAir Home platform. The platform allows patients to self-monitor their respiratory health and share clinically relevant data with their care teams, who can view these data remotely via a healthcare portal. Other key findings show that patient adherence to self-monitoring schedules is high and that the technology is well accepted by patients and parents.

CLINICAL STUDY

#coaching

#rpm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY